Drug Profile

VY HTT01

Alternative Names: Huntington's disease gene therapy - Voyager Therapeutics; VY-HTT01

Latest Information Update: 31 Mar 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Voyager Therapeutics
Class Antiparkinsonians; Gene therapies; Neuroprotectants
Mechanism of Action Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Huntington's disease
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Discontinued Huntington's disease

Most Recent Events

16 Aug 2021 Voyager Therapeutics terminates a phase I trial in Huntington's disease before initiation of enrollment (NCT04885114)
09 Aug 2021 Discontinued - Preclinical for Huntington's disease in USA (Parenteral) as at August 2021
23 May 2021 VY HTT01 is available for licensing as of 19 May 2021

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com